...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Short Stature and Thyroxine-Binding Globulin Excess: Improvement With Triiodothyronine Treatment
【24h】

Short Stature and Thyroxine-Binding Globulin Excess: Improvement With Triiodothyronine Treatment

机译:身材矮小和甲状腺素结合球蛋白过多:三碘甲状腺素治疗改善

获取原文
           

摘要

Thyroxine-binding globulin (TBG) excess with increased total thyroxine (T4) and triiodothyronine (T3) levels has not been thought to produce symptoms. We report on a white boy, initially seen at 4.3 years of age and observed for 4 years, who has short stature caused by the excess thyroxine binding. At his initial examination his thyroxine-binding globulin (TBG) levels were elevated (17 mg/dL), and he had a T4 level of 25.8 μg/dL, short stature, a bone age of 19 months, normal vital signs, and hyperthyroid-stimulating hormone (TSH) response to thyrotropin-releasing hormone (TRH) testing (maximal value 58 μIU/mL). Results of tests obtained during the next 6 months showed other abnormalities related to thyroid function. Tests showed the following values: T3 412 ng/dL, thyroid uptake 24%, and low T3 resin uptake. They also showed these values: an elevated basal TSH of 8.7 μIU/mL, a slightly low preejection period to left ventricular ejection time ratio of 0.29 (normal 0.35 ± 0.04), and WISC-R IQ within normal limits. Because of the persistent short stature, T3 supplementation was started at age 7 years and gradually increased to 35 μg/d. The patient showed no thyrotoxic symptoms. Serum T4 level decreased from 25.8 to 4.2 μg/dL, T3 increased to 1,240 ng/dL, the TRH/TSH test result was suppressed (maximal level 1.8), and the preejection period to left ventricular ejection time ratio decreased to 0.24. Growth velocity increased by 65%. Both of the child's parents had normal thyroid test results. A younger brother also showed similar elevations of TBG level and even greater T4 values (36 μg/dL). His height has remained at the 25th percentile. This observation is the first report of the recessive transmission of TBG excess and suggests an associated thyroid-dependent short stature that is correctable with treatment.
机译:甲状腺素结合球蛋白(TBG)过多,总甲状腺素(T4)和三碘甲状腺素(T3)水平升高,尚未被认为会产生症状。我们报道了一个白人男孩,最初见于4.3岁,被观察了4年,由于甲状腺素结合过多而身材矮小。初次检查时,他的甲状腺素结合球蛋白(TBG)水平升高(17 mg / dL),T4水平为25.8μg/ dL,身材矮小,骨龄为19个月,生命体征正常,甲状腺功能亢进-促甲状腺激素(TSH)对促甲状腺激素释放激素(TRH)测试的反应(最大值58μIU/ mL)。在接下来的6个月中获得的测试结果显示,其他异常与甲状腺功能有关。测试显示以下值:T3 412 ng / dL,甲状腺摄取24%和低T3树脂摄取。他们还显示了这些值:基础TSH升高至8.7μIU/ mL,射血前期与左室射血时间的比值略低,为0.29(正常值为0.35±0.04),并且WISC-R IQ在正常范围内。由于持续的矮小身材,T3补充剂始于7岁,并逐渐增加至35μg/ d。该患者未显示甲状腺毒性症状。血清T4水平从25.8降至4.2μg/ dL,T3增加至1,240 ng / dL,TRH / TSH测试结果受到抑制(最大水平为1.8),并且射血前期与左心室射血时间之比降低至0.24。生长速度提高了65%。孩子的父母双方甲状腺检查结果均正常。一个弟弟也表现出相似的TBG水平升高,甚至更高的T4值(36μg/ dL)。他的身高一直保持在第25个百分点。该观察结果是TBG过量隐性传播的首次报道,并暗示了相关的甲状腺依赖性矮小身材,可通过治疗纠正。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号